Pathogenesis of asthma: Implications for precision medicine

Clinical Science

Volumn 131, Issue 14, 2017, Pages 1723-1735

  Russell, Richard J ^a   Brightling, Christopher E ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AIRWAY REMODELING; ASTHMA; COMORBIDITY; GENETICS; HUMAN; PATHOGENESIS; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RESPIRATORY TRACT ALLERGY; RESPIRATORY TRACT INFLAMMATION; REVIEW; COMPLICATION; EOSINOPHILIA; GENETIC PREDISPOSITION; INFLAMMATION; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; RESPIRATORY HYPERSENSITIVITY;

AIRWAY REMODELING; ASTHMA; EOSINOPHILIA; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; PRECISION MEDICINE; RESPIRATORY HYPERSENSITIVITY;

EID: 85021853693     PISSN: 01435221     EISSN: 14708736     Source Type: Journal    
DOI: 10.1042/CS20160253     Document Type: Review

References (92)

1. Bousquet, J., Mantzouranis, E., Cruz, A.A., Ait-Khaled, N., Baena-Cagnani, C.E., Bleecker, E.R. et al. (2010) Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J. Allergy. Clin. Immunol. 126, 926-938
2. Global Initiative for Asthma (GINA) (2016) Global strategy for asthma management and prevention
3. British Thoracic Society/Scottish Intercollegiate Guidelines Network (2016) British guideline on the management of asthma. https://www.brit-thoracic.org.uk
4. National Heart, Lung, and Blood Institute (2007) National Asthma Education and Prevention Program, Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma
5. Chung, K.F., Wenzel, S.E., Brozek, J.L., Bush, A., Castro, M., Sterk, P.J. et al. (2014) International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur. Respir. J. 43, 343-373
6. Wenzel, S.E. (2012) Asthma phenotypes: the evolution from clinical to molecular approaches. Nat. Med. 18, 716-725
7. Haldar, P., Pavord, I.D., Shaw, D.E., Berry, M.A., Thomas, M., Brightling, C.E. et al. (2008) Cluster analysis and clinical asthma phenotypes. Am. J. Respir. Crit. Care Med. 178, 218-224
8. Lotvall, J., Akdis, C.A., Bacharier, L.B., Bjermer, L., Casale, T.B., Custovic, A. et al. (2011) Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J. Allergy Clin. Immunol. 127, 355-360
9. Koczulla, A.R., Vogelmeier, C.F., Garn, H. and Renz, H. (2017) New concepts in asthma: clinical phenotypes and pathophysiological mechanisms. Drug Discov. Today 22, 388-396
10. Fuchs, O., Bahmer, T., Rabe, K.F. and von Mutius, E. (2017) Asthma transition from childhood into adulthood. Lancet Respir. Med. 5, 224-234
11. Moffatt, M.F., Gut, I.G., Demenais, F., Strachan, D.P., Bouzigon, E., Heath, S. et al. (2010) A large-scale, consortium-based genomewide association study of asthma. N. Engl. J. Med. 363, 1211-1221
12. Ramasamy, A., Kuokkanen, M., Vedantam, S., Gajdos, Z.K., Couto Alves, A., Lyon, H.N. et al. (2012) Genome-wide association studies of asthma in population-based cohorts confirm known and suggested loci and identify an additional association near HLA. PLoS ONE 7, e44008
13. Moffatt, M.F., Kabesch, M., Liang, L., Dixon, A.L., Strachan, D., Heath, S. et al. (2007) Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. Nature 448, 470-473
14. Bonnelykke, K., Sleiman, P., Nielsen, K., Kreiner-Moller, E., Mercader, J.M., Belgrave, D. et al. (2014) A genome-wide association study identifies CDHR3 as a susceptibility locus for early childhood asthma with severe exacerbations. Nat. Genet. 46, 51-55
15. Wan, Y.I., Shrine, N.R., Soler Artigas, M., Wain, L.V., Blakey, J.D., Moffatt, M.F. et al. (2012) Genome-wide association study to identify genetic determinants of severe asthma. Thorax 67, 762-768
16. McGeachie, M.J., Yates, K.P., Zhou, X., Guo, F., Sternberg, A.L., Van Natta, M.L. et al. (2016) Genetics and genomics of longitudinal lung function patterns in asthmatics. Am. J. Respir. Crit. Care. Med. 194, 1465-1474
17. Green, R.H., Brightling, C.E., Woltmann, G., Parker, D., Wardlaw, A.J. and Pavord, I.D. (2002) Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 57, 875-879
18. McGrath, K.W., Icitovic, N., Boushey, H.A., Lazarus, S.C., Sutherland, E.R., Chinchilli, V.M. et al. (2012) A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am. J. Respir. Crit. Care Med. 185, 612-619
19. Douwes, J., Gibson, P., Pekkanen, J. and Pearce, N. (2002) Non-eosinophilic asthma: importance and possible mechanisms. Thorax 57, 643-648
20. Eltboli, O. and Brightling, C.E. (2013) Eosinophils as diagnostic tools in chronic lung disease. Expert Rev. Respir. Med. 7, 33-42
21. Lambrecht, B.N. and Hammad, H. (2015) The immunology of asthma. Nat. Immunol. 16, 45-56
22. Boorsma, M., Lutter, R., van de Pol, M.A., Out, T.A., Jansen, H.M., Jonkers, R.E. et al. (2007) Repeatability of inflammatory parameters in induced sputum of COPD patients. Copd 4, 321-329
23. Pizzichini, E., Pizzichini, M.M., Efthimiadis, A., Evans, S., Morris, M.M., Squillace, D. et al. (1996) Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am. J. Respir. Crit. Care. Med. 154, 308-317
24. Kulkarni, N.S., Hollins, F., Sutcliffe, A., Saunders, R., Shah, S., Siddiqui, S. et al. (2010) Eosinophil protein in airway macrophages: a novel biomarker of eosinophilic inflammation in patients with asthma. J. Allergy Clin. Immunol. 126, 61.e3-9.e3
25. Jatakanon, A., Lim, S. and Barnes, P.J. (2000) Changes in sputum eosinophils predict loss of asthma control. Am. J. Respir. Crit. Care Med. 161, 64-72
26. Hanania, N.A., Noonan, M., Corren, J., Korenblat, P., Zheng, Y., Fischer, S.K. et al. (2015) Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax 70, 748-756
27. Heaney, L.G., Djukanovic, R., Woodcock, A., Walker, S., Matthews, J.G., Pavord, I.D. et al. (2016) Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK). Thorax 71, 187-189
28. Kaur, D. and Brightling, C. (2012) OX40/OX40 ligand interactions in T-cell regulation and asthma. Chest 141, 494-499
29. Gauvreau, G.M., Boulet, L.P., Cockcroft, D.W., FitzGerald, J.M., Mayers, I., Carlsten, C. et al. (2014) OX40L blockade and allergen-induced airway responses in subjects with mild asthma. Clin. Exp. Allergy 44, 29-37
30. Gauvreau, G.M., O'Byrne, P.M., Boulet, L.P., Wang, Y., Cockcroft, D., Bigler, J. et al. (2014) Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N. Engl. J. Med. 370, 2102-2110
31. Denburg, J.A. (1998) The origins of basophils and eosinophils in allergic inflammation. J. Allergy Clin. Immunol. 102, S74-S746
32. Sehmi, R., Wood, L.J., Watson, R., Foley, R., Hamid, Q., O'Byrne, P.M. et al. (1997) Allergen-induced increases in IL-5 receptor alpha-subunit expression on bone marrow-derived CD34+ cells from asthmatic subjects. A novel marker of progenitor cell commitment towards eosinophilic differentiation. J. Clin. Invest. 100, 2466-2475
33. Wood, L.J., Inman, M.D., Watson, R.M., Foley, R., Denburg, J.A. and O'Byrne, P.M. (1998) Changes in bone marrow inflammatory cell progenitors after inhaled allergen in asthmatic subjects. Am. J. Respir. Crit. Care Med. 157, 99-105
34. George, L. and Brightling, C.E. (2016) Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Ther. Adv. Chronic Dis. 7, 34-51
35. Fulkerson, P.C. and Rothenberg, M.E. (2013) Targeting eosinophils in allergy, inflammation and beyond. Nat. Rev. Drug Discov. 12, 117-129
36. Luijk, B., Lindemans, C.A., Kanters, D., van der Heijde, R., Bertics, P., Lammers, J.W. et al. (2005) Gradual increase in priming of human eosinophils during extravasation from peripheral blood to the airways in response to allergen challenge. J. Allergy Clin. Immunol. 115, 997-1003
37. Fukuda, T., Fukushima, Y., Numao, T., Ando, N., Arima, M., Nakajima, H. et al. (1996) Role of interleukin-4 and vascular cell adhesion molecule-1 in selective eosinophil migration into the airways in allergic asthma. Am. J. Respir. Cell Mol. Biol. 14, 84-94
38. Symon, F.A., Lawrence, M.B., Williamson, M.L., Walsh, G.M., Watson, S.R. and Wardlaw, A.J. (1996) Functional and structural characterization of the eosinophil P-selectin ligand. J. Immunol. 157, 1711-1719
39. Patel, K.D. (1998) Eosinophil tethering to interleukin-4-activated endothelial cells requires both P-selectin and vascular cell adhesion molecule-1. Blood 92, 3904-3911
40. Woltmann, G., McNulty, C.A., Dewson, G., Symon, F.A. and Wardlaw, A.J. (2000) Interleukin-13 induces PSGL-1/P-selectin-dependent adhesion of eosinophils, but not neutrophils, to human umbilical vein endothelial cells under flow. Blood 95, 3146-3152
41. Pease, J.E. (2006) Asthma, allergy and chemokines. Curr. Drug Targets 7, 3-12
42. Brightling, C.E. (2011) Eosinophils, bronchitis and asthma: pathogenesis of cough and airflow obstruction. Pulm. Pharmacol. Ther. 24, 324-327
43. Laidlaw, T.M. and Boyce, J.A. (2012) Cysteinyl leukotriene receptors, old and new; implications for asthma. Clin. Exp. Allergy 42, 1313-1320
44. Stinson, S.E., Amrani, Y. and Brightling, C.E. (2015) D prostanoid receptor 2 (chemoattractant receptor-homologous molecule expressed on TH2 cells) protein expression in asthmatic patients and its effects on bronchial epithelial cells. J. Allergy Clin. Immunol. 135, 395-406
45. Hirai, H., Tanaka, K., Yoshie, O., Ogawa, K., Kenmotsu, K., Takamori, Y. et al. (2001) Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J. Exp. Med. 193, 255-261
46. Gonem, S., Berair, R., Singapuri, A., Hartley, R., Laurencin, M.F., Bacher, G. et al. (2016) Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir. Med. 4, 699-707
47. ClinicalTrials.gov Clinical Studies Registry. https://clinicaltrials.gov/ (accessed on March 7, 2017)
48. Beale, J., Jayaraman, A., Jackson, D.J., Macintyre, J.D., Edwards, M.R., Walton, R.P. et al. (2014) Rhinovirus-induced IL-25 in asthma exacerbation drives type 2 immunity and allergic pulmonary inflammation. Sci. Transl. Med. 6, 256ra134
49. Lloyd, C.M. (2010) IL-33 family members and asthma-bridging innate and adaptive immune responses. Curr. Opin. Immunol. 22, 800-806
50. Mitchell, P.D. and O'Byrne, P.M. (2017) Biologics and the lung: TSLP and other epithelial cell-derived cytokines in asthma. Pharmacol. Ther. 169, 104-112
51. Artis, D. and Spits, H. (2015) The biology of innate lymphoid cells. Nature 517, 293-301
52. Wenzel, S., Ford, L., Pearlman, D., Spector, S., Sher, L., Skobieranda, F. et al. (2013) Dupilumab in persistent asthma with elevated eosinophil levels. N. Engl. J. Med. 368, 2455-2466
53. Hanania, N.A., Korenblat, P., Chapman, K.R., Bateman, E.D., Kopecky, P., Paggiaro, P. et al. (2016) Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir. Med. 4, 781-796
54. Brightling, C.E., Chanez, P., Leigh, R., O'Byrne, P.M., Korn, S., She, D. et al. (2015) Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir. Med. 3, 692-701
55. Ortega, H.G., Liu, M.C., Pavord, I.D., Brusselle, G.G., FitzGerald, J.M., Chetta, A. et al. (2014) Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med. 371, 1198-1207
56. Haldar, P., Brightling, C.E., Hargadon, B., Gupta, S., Monteiro, W., Sousa, A. et al. (2009) Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med. 360, 973-984
57. Pavord, I.D., Korn, S., Howarth, P., Bleecker, E.R., Buhl, R., Keene, O.N. et al. (2012) Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. The Lancet 380, 651-659
58. Bel, E.H., Wenzel, S.E., Thompson, P.J., Prazma, C.M., Keene, O.N., Yancey, S.W. et al. (2014) Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N. Engl. J. Med. 371, 1189-1197
59. Castro, M., Zangrilli, J., Wechsler, M.E., Bateman, E.D., Brusselle, G.G., Bardin, P. et al. (2015) Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir. Med. 3, 355-366
60. Bleecker, E.R., FitzGerald, J.M., Chanez, P., Papi, A., Weinstein, S.F., Barker, P. et al. (2016) Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 388, 2115-2127
61. FitzGerald, J.M., Bleecker, E.R., Nair, P., Korn, S., Ohta, K., Lommatzsch, M. et al. (2016) Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 288, 2128-2141
62. Choy, D.F., Hart, K.M., Borthwick, L.A., Shikotra, A., Nagarkar, D.R., Siddiqui, S. et al. (2015) TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma. Sci. Transl. Med. 7, 301ra129
63. Gupta, S., Siddiqui, S., Haldar, P., Raj, J.V., Entwisle, J.J., Wardlaw, A.J. et al. (2009) Qualitative analysis of high-resolution CT scans in severe asthma. Chest 136, 1521-1528
64. Thomson, N.C. (2016) Novel approaches to the management of noneosinophilic asthma. Ther. Adv. Respir. Dis. 10, 211-234
65. Baines, K.J., Simpson, J.L., Scott, R.J. and Gibson, P.G. (2009) Immune responses of airway neutrophils are impaired in asthma. Exp. Lung Res. 35, 554-569
66. Essilfie, A.T., Simpson, J.L., Dunkley, M.L., Morgan, L.C., Oliver, B.G., Gibson, P.G. et al. (2012) Combined Haemophilus influenzae respiratory infection and allergic airways disease drives chronic infection and features of neutrophilic asthma. Thorax 67, 588-599
67. Brusselle, G.G., Vanderstichele, C., Jordens, P., Deman, R., Slabbynck, H., Ringoet, V. et al. (2013) Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax 68, 322-329
68. Johnston, S.L., Szigeti, M., Cross, M., Brightling, C., Chaudhuri, R., Harrison, T. et al. (2016) Azithromycin for Acute Exacerbations of Asthma: The AZALEA Randomized Clinical Trial. JAMA Intern. Med. 176, 1630-1637
69. Doe, C., Bafadhel, M., Siddiqui, S., Desai, D., Mistry, V., Rugman, P. et al. (2010) Expression of the T helper 17-associated cytokines IL-17A and IL-17F in asthma and COPD. Chest 138, 1140-1147
70. Busse, W.W., Holgate, S., Kerwin, E., Chon, Y., Feng, J., Lin, J. et al. (2013) Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am. J. Respir. Crit. Care Med. 188, 1294-1302
71. Brightling, C.E., Bradding, P., Symon, F.A., Holgate, S.T., Wardlaw, A.J. and Pavord, I.D. (2002) Mast-cell infiltration of airway smooth muscle in asthma. N. Engl. J. Med. 346, 1699-1705
72. Brightling, C.E., Ammit, A.J., Kaur, D., Black, J.L., Wardlaw, A.J., Hughes, J.M. et al. (2005) The CXCL10/CXCR3 axis mediates human lung mast cell migration to asthmatic airway smooth muscle. Am. J. Respir. Crit. Care Med. 171, 1103-1108
73. Brightling, C.E., Symon, F.A., Holgate, S.T., Wardlaw, A.J., Pavord, I.D. and Bradding, P. (2003) Interleukin-4 and-13 expression is co-localized to mast cells within the airway smooth muscle in asthma. Clin. Exp. Allergy 33, 1711-1716
74. Cahill, K.N., Katz, H.R., Cui, J., Lai, J., Kazani, S., Crosby-Thompson, A., Garofalo, D., Castro, M., Jarjour, N., DiMango, E., Erzurum, S., Trevor, J.L., Shenoy, K., Chinchilli, V.M., Wechsler, M.E., Laidlaw, T.M., Boyce, J.A. and Israel, E. (2017) KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma. N. Engl. J. Med. 376, 1911-1920, 28514613, doi:10.1056/NEJMoa1613125
75. Kaur, D., Saunders, R., Hollins, F., Woodman, L., Doe, C., Siddiqui, S. et al. (2010) Mast cell fibroblastoid differentiation mediated by airway smooth muscle in asthma. J. Immunol. 185, 6105-6114
76. Sutcliffe, A., Hollins, F., Gomez, E., Saunders, R., Doe, C., Cooke, M. et al. (2012) Increased nicotinamide adenine dinucleotide phosphate oxidase 4 expression mediates intrinsic airway smooth muscle hypercontractility in asthma. Am. J. Respir. Crit. Care Med. 185, 267-274
77. Di Candia, L., Gomez, E., Venereau, E., Chachi, L., Kaur, D., Bianchi, M.E. et al. (2017) HMGB1 is upregulated in the airways in asthma and potentiates airway smooth muscle contraction via TLR4. J. Allergy Clin. Immunol, in press, doi:10.1183/13993003.01507-2016
78. Berair, R. and Brightling, C.E. (2014) Asthma therapy and its effect on airway remodelling. Drugs 74, 1345-1369
79. Wardlaw, A.J., Brightling, C., Green, R., Woltmann, G. and Pavord, I. (2000) Eosinophils in asthma and other allergic diseases. Br. Med. Bull. 56, 985-1003
80. Berair, R., Hartley, R., Mistry, V., Sheshadri, A., Gupta, S., Singapuri, A. et al. (2017) Associations in asthma between quantitative computed tomography and bronchial biopsy-derived airway remodelling. Eur. Respir. J. 49, in press
81. Thomas, B., Rutman, A., Hirst, R.A., Haldar, P., Wardlaw, A.J., Bankart, J. et al. (2010) Ciliary dysfunction and ultrastructural abnormalities are features of severe asthma. J. Allergy Clin. Immunol. 126, 722.e2-729.e2
82. Pretolani, M., Dombret, M.C., Thabut, G., Knap, D., Hamidi, F., Debray, M.P. et al. (2014) Reduction of airway smooth muscle mass by bronchial thermoplasty in patients with severe asthma. Am. J. Respir. Crit. Care Med. 190, 1452-1454
83. Chakir, J., Haj-Salem, I., Gras, D., Joubert, P., Beaudoin, E.L., Biardel, S. et al. (2015) Effects of bronchial thermoplasty on airway smooth muscle and collagen deposition in asthma. Ann. Am. Thorac. Soc. 12, 1612-1618
84. Denner, D.R., Doeing, D.C., Hogarth, D.K., Dugan, K., Naureckas, E.T. and White, S.R. (2015) Airway inflammation after bronchial thermoplasty for severe asthma. Ann. Am. Thorac. Soc. 12, 1302-1309
85. Pretolani, M., Bergqvist, A., Thabut, G., Dombret, M.C., Knapp, D., Hamidi, F. et al. (2016) Effectiveness of bronchial thermoplasty in patients with severe refractory asthma: Clinical and histopathologic correlations. J. Allergy. Clin. Immunol. 139, 1176-1185
86. Castro, M., Rubin, A.S., Laviolette, M., Fiterman, J., De Andrade Lima, M., Shah, P.L. et al. (2010) Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am. J. Respir. Crit. Care. Med. 181, 116-124
87. Saunders, R., Kaul, H., Berair, R., Singapuri, A., Chernyavsky, I., Chachi, L. et al. (2017) Fevipiprant (QAW039) reduces airway smooth muscle mass in asthma via antagonism of the prostaglandin D2 receptor 2 (DP2). Am. J. Respir. Crit. Care. Med. 195, A4677
88. Girodet, P.O., Dournes, G., Thumerel, M., Begueret, H., Dos Santos, P., Ozier, A. et al. (2015) Calcium channel blocker reduces airway remodeling in severe asthma. A proof-of-concept study. Am. J. Respir. Crit. Care Med. 191, 876-883
89. Manuyakorn, W. (2014) Airway remodelling in asthma: role for mechanical forces. Asia Pac. Allergy 4, 19-24
90. Boulet, L.P. and Boulay, M.E. (2011) Asthma-related comorbidities. Expert Rev. Respir. Med. 5, 377-393
91. Serafino-Agrusa, L., Spatafora, M. and Scichilone, N. (2015) Asthma and metabolic syndrome: Current knowledge and future perspectives. World J. Clin. Cases 3, 285-292
92. Fattahi, F., Hylkema, M.N., Melgert, B.N., Timens, W., Postma, D.S. and ten Hacken, N.H. (2011) Smoking and nonsmoking asthma: differences in clinical outcome and pathogenesis. Expert Rev. Respir. Med. 5, 93-105